Sera Prognostics (SERA) Non-Current Deffered Revenue (2020 - 2021)

Sera Prognostics' (SERA) quarterly Non-Current Deffered Revenue came in at $35000.0 in Q3 2021, down 82.5% on a QoQ basis from $200000.0 in Q2 2021.

Sera Prognostics (SERA) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends

Sera Prognostics (SERA) has 2 years of Non-Current Deffered Revenue data on file, last reported at $35000.0 in Q3 2021.

Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $35000.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $35000.0 (changed N/A YoY) and the FY2020 annual result came in at $300000.0, changed N/A from the prior year.
Non-Current Deffered Revenue fell to $35000.0 in Q3 2021, from $200000.0 in the prior quarter.
In the past five years, Non-Current Deffered Revenue ranged from a high of $300000.0 in Q4 2020 to a low of $35000.0 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	-
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	-
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	-
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	-
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	-
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	-
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	-
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	539.34 Mn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	-
10	Sera Prognostics	103.48 Mn	103.48 Mn	-20,000.00	-

Download Data